BRKR on Nasdaq

Bruker

Logo: Guigui2306, CC BY-SA 4.0, via Wikimedia Commons5

American scientific instrument manufacturer

Bruker Corporation is an American manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis. It is headquartered in Billerica, Massachusetts, and is the publicly traded parent company of Bruker Scientific Instruments (Bruker AXS, Bruker BioSpin, Bruker Daltonics and Bruker Optics) and Bruker Energy & Supercon Technologies (BEST) divisions. In April 2010, Bruker created a Chemical Analysis Division (headquartered in Fremont, CA) under the Bruker Daltonics subsidiary.3 It was founded by Günther Laukien.1 Its shares trade on Nasdaq under the symbol BRKR.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$3.4BRevenue, fiscal 20256
-$8.6MNet income, fiscal 20256
1960Founded1

Compare with Waters Corporation, Mettler Toledo or Revvity Inc., or pick any stock.

  • TickerBRKR on Nasdaq1
  • IndustryLaboratory Analytical Instruments1
  • HeadquartersBillerica1
  • Websitewww.bruker.com
  • Legal formDelaware corporation1
  • Incorporated inDE7
  • Business address40 Manning Rd, Billerica, Ma 018217
  • Filer categoryLarge accelerated filer7
  • LEILEBZ6VLQ6I8XB1NHVY154
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 31566834

Bruker Corporation is an American manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis. It is headquartered in Billerica, Massachusetts, and is the publicly traded parent company of Bruker Scientific Instruments (Bruker AXS, Bruker BioSpin, Bruker Daltonics and Bruker Optics) and Bruker Energy & Supercon Technologies (BEST) divisions.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

45.9%Gross margin6
2.0%Operating margin6
-0.3%Net margin6
2.1%Revenue growth, 20256
-0.4%Return on equity6
0.75×Debt to equity6
$43.3MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 81% of the revenue Bruker broke down this way in fiscal 2025.

  1. Product$2.8B681%up 0% from 2024
  2. Product and Service, Other$670.1M619%up 10% from 2024
Products and services by year
Products and services202320242025
Product$2.5B$2.8B$2.8B
Product and Service, Other$506.9M$607.2M$670.1M

Business segments

Bsi Calid brought in 35% of the revenue Bruker broke down this way in fiscal 2025.

  1. Bsi Calid$1.2B635%up 11% from 2024
  2. Bsi Nano$1.1B631%down 1% from 2024
  3. BSI BioSpin$878.8M626%down 3% from 2024
  4. Energy And Supercon Technologies$270.9M68%down 4% from 2024
Business segments by year
Business segments202320242025
Bsi Calid$960.4M$1.1B$1.2B
Bsi Nano$941.9M$1.1B$1.1B
BSI BioSpin$798.5M$905.7M$878.8M
Energy And Supercon Technologies$280.7M$283.0M$270.9M

Regions

Europe, Excluding Germany brought in 28% of the revenue Bruker broke down this way in fiscal 2025.

  1. Europe, Excluding Germany$950.2M628%up 9% from 2024
  2. United States$891.3M626%down 5% from 2024
  3. Asia Pacific Excluding China$552.6M616%up 7% from 2024
  4. China$475.8M614%up 1% from 2024
  5. Germany$297.0M69%down 4% from 2024
  6. Other Country$269.6M68%up 6% from 2024
Regions by year
Regions202320242025
Europe, Excluding Germany$699.7M$873.0M$950.2M
United States$777.7M$938.5M$891.3M
Asia Pacific Excluding China$460.9M$518.5M$552.6M
China$528.1M$471.2M$475.8M
Germany$281.5M$310.7M$297.0M
Other Country$216.6M$254.5M$269.6M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue54¢$1.9B
  • Research and development12¢$395.2M
  • Selling, general and admin28¢$946.5M
  • Other costs6¢$206.7M
  • Income tax1¢$29.3M

Out of $3.4B in revenue.6 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending68¢$90.8M
  • Dividends paid17¢$22.8M
  • Share buybacks7¢$10.0M
  • Kept or used elsewhere8¢$10.5M

Out of $134.1M of cash from operations.6

Financial statements

Revenue10111213146$3.4B in 2025+81% since 2018
0$1.0B$2.0B$3.0B$4.0B2018: $1.9B$1.9B20182019: $2.1B$2.1B2019+9%2020: $2.0B$2.0B2020−4%2021: $2.4B$2.4B2021+22%2022: $2.5B$2.5B2022+5%2023: $3.0B$3.0B2023+17%2024: $3.4B$3.4B2024+14%2025: $3.4B$3.4B2025+2%
Gross profit10111213146$1.6B in 2025+75% since 2018
0$500.0M$1.0B$1.5B$2.0B2018: $900.0M$900.0M20182019: $995.3M$995.3M2019+11%2020: $939.8M$939.8M2020−6%2021: $1.2B$1.2B2021+29%2022: $1.3B$1.3B2022+8%2023: $1.5B$1.5B2023+16%2024: $1.6B$1.6B2024+9%2025: $1.6B$1.6B2025−4%
Operating income10111213146$68.2M in 2025−74% since 2018
0$200.0M$400.0M$600.0M2018: $262.4M$262.4M20182019: $300.9M$300.9M2019+15%2020: $248.3M$248.3M2020−17%2021: $413.3M$413.3M2021+66%2022: $432.7M$432.7M2022+5%2023: $436.9M$436.9M2023+1%2024: $253.1M$253.1M2024−42%2025: $68.2M$68.2M2025−73%
Net income10111213146-$8.6M in 2025
-$200.0M0$200.0M$400.0M$600.0M2018: $179.7M$179.7M20182019: $197.2M$197.2M2019+10%2020: $157.8M$157.8M2020−20%2021: $277.1M$277.1M2021+76%2022: $296.6M$296.6M2022+7%2023: $427.2M$427.2M2023+44%2024: $113.1M$113.1M2024−74%2025: -$8.6M-$8.6M2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-12-312024-12-312023-12-31
Total revenue$3.4B$3.4B$3.0B
Total cost of revenue$1.9B$1.7B$1.5B
Gross profit$1.6B$1.6B$1.5B
Selling, general and administrative$946.5M$893.8M$729.4M
Research and development$395.2M$376.5M$294.8M
Goodwill impairment charge$96.5M$0$0
Other charges, net$71.3M$126.1M$52.2M
Total operating expenses$1.5B$1.4B$1.1B
Operating income$68.2M$253.1M$436.9M
Bargain purchase gain and associated measurement period adjustments$0-$8.0M$144.1M
Interest and other expense, net-$46.2M-$38.2M-$36.8M
Income before income taxes, equity in (losses) income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries$22.0M$206.9M$544.2M
Income tax provision$29.3M$91.4M$117.7M
Equity in (losses) income of unconsolidated investees, net of tax-$1.0M-$1.7M$2.0M
Consolidated net (loss) income-$8.3M$113.8M$428.5M
Net income attributable to noncontrolling interests in consolidated subsidiaries$300.0K$700.0K$1.3M
Net (loss) income attributable to Bruker Corporation-$8.6M$113.1M$427.2M
Dividends on Series A Mandatory Convertible Preferred Stock$13.9M$0$0
Net (loss) income attributable to Bruker Corporation common shareholders-$22.5M$113.1M$427.2M
Basic-$0.15$0.76$2.92
Diluted-$0.15$0.76$2.90
Basic151.8M shares149.0M shares146.4M shares
Diluted151.8M shares149.5M shares147.2M shares

Compare Bruker with another company

Corporate structure

Bruker sits at the top of its group. 124 entities, 33 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Bruker

  • Bruker Billerica, Massachusetts, United States
    • Bruker (France) Subsidiary · Wissembourg, France
    • Anasys Instruments Corporation Subsidiary · California, United States
    • Biocrates Inc. Subsidiary · Delaware, United States
    • Biocrates Life Sciences AG Subsidiary · Austria
    • Biognosys, AG Subsidiary · Switzerland
    • BLI Europe International, LTD Subsidiary · United Kingdom
    • BLI International LLC Subsidiary · Delaware, United States
    • Bruker (Beijing) Scientific Technology Co., Ltd. Subsidiary · China
    • Bruker (Canada) Subsidiary · Canada
    • Bruker (Israel) Subsidiary · Israel
    • BRUKER (MALAYSIA) SDN. BHD. Subsidiary · Shah Alam, Malaysia
    • Bruker (United States) Subsidiary · United States
    • Bruker Arabia Limited Subsidiary · Saudi Arabia
    • Bruker Austria GmbH Subsidiary · Austria
    • Bruker AXS Holdings, Inc. Subsidiary · Delaware, United States
    • Bruker AXS LLC Subsidiary · Delaware, United States
    • Bruker Belgium S.A./N.V. Subsidiary · Belgium
    • Bruker BioSpin Corporation Subsidiary · Massachusetts, United States
    • Bruker BioSpin GmbH & Co. KG Subsidiary · Germany
    • Bruker BioSpin Holding SE Subsidiary · Germany
    • Bruker BioSpin Verwaltungs GmbH Subsidiary · Germany
    • Bruker Business Support Center sp. Z.o.o. Subsidiary · Poland
    • Bruker Cellular Analysis, Inc. Subsidiary · Delaware, United States
    • Bruker Daltonics GmbH & Co., KG Subsidiary · Germany
    • Bruker Daltonics Ltd. Subsidiary · United Kingdom
    • and 98 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Bruker reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.4B6 Dec 31, 2025$1.2B6 Dec 31, 2024+17.0%
Accumulated depreciation$692.0M6 Dec 31, 2025$559.0M6 Dec 31, 2024+23.8%
Property and equipment, net$744.8M6 Dec 31, 2025$669.3M6 Dec 31, 2024+11.3%
Finance-lease assets$20.3M6 Dec 31, 2025$18.8M6 Dec 31, 2024+8.0%
Operating-lease assets (leased space)$165.8M6 Dec 31, 2025$145.5M6 Dec 31, 2024+14.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$298.8M6 Dec 31, 2025$183.4M6 Dec 31, 2024+62.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.5B6 Dec 31, 2025$1.5B6 Dec 31, 2024+2.7%
Intangible assets, net (excluding goodwill)$899.6M6 Dec 31, 2025$912.5M6 Dec 31, 2024−1.4%
Indefinite-lived intangibles (excluding goodwill)$3.2M6 Dec 31, 2025$2.8M6 Dec 31, 2024+14.3%
Finite-lived intangibles, gross$1.5B6 Dec 31, 2025$1.4B6 Dec 31, 2024+8.5%
Accumulated amortization$568.3M6 Dec 31, 2025$440.0M6 Dec 31, 2024+29.2%
Finite-lived intangibles, net$899.6M6 Dec 31, 2025$912.5M6 Dec 31, 2024−1.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$1.1B6 Dec 31, 2025$1.1B6 Dec 31, 2024+2.5%
Raw materials$392.0M6 Dec 31, 2025$388.7M6 Dec 31, 2024+0.8%
Work in process$343.6M6 Dec 31, 2025$348.9M6 Dec 31, 2024−1.5%
Finished goods$243.1M6 Dec 31, 2025$228.5M6 Dec 31, 2024+6.4%

Properties, in its own words

We believe that our existing principal facilities are well maintained and in good operating condition and that they are adequate for our foreseeable business needs.

In addition to the principal facilities noted below, we lease additional facilities for sales, applications, and service support in various countries throughout the world. If we should require additional or alternative facilities, we believe that such facilities can be obtained on short notice at competitive rates.

The rest of Item 2

The location and primary use of our principal properties used in current operations are as follows:

Principal Use

Segment · Location · ApproximateSquare Feet · Owned/Leased · Manufacturing · Research & Development · Application & Development · Marketing · Sales & Administration

BSI BioSpin · Wissembourg, France · 219,745 · Owned · Magnetic Resonance Preclinical Imaging · X · X · X · X

Ettlingen, Germany · 179,399 · Owned · Preclinical Imaging · X · X · X · X

Faellanden, Switzerland · 346,27561,918 · OwnedLeased · Magnetic Resonance Preclinical Imaging · X · X · X · X

BSI CALID · Berlin, Germany · 23,81022,916 · OwnedLeased · Consumables & Instruments · X · X · X · X

Bremen, Germany · 272,743 · Owned · Mass Spectrometry · X · X · X · X

Ettlingen, Germany · 215,385 · Owned · Mass SpectrometryCBRNE Detection · X · X · X · X

Nehren, Germany · 103,753 · Owned · Consumables & Instruments · X · X · X · X

Faellanden, Switzerland · 18,460 · Leased · Mass Spectrometry · X · X · X

BSI NANO · Graz, Austria · 33,368 · Leased · Optical-based Metrology · X · X · X · X

Berlin, Germany · 110,677 · Owned · BioAFMX-Ray · X · X · X · X

Karlsruhe, Germany · 146,00058,000 · OwnedLeased · S-OESX-Ray · X · X · X · X

Migdal HaEmek, Israel · 46,300 · Leased · X-Ray · X · X · X · X

Penang, Malaysia · 101,700 · Leased · X-RayS-OESAFM · X · X

Bothell, Washington · 57,784 · Leased · Spatial Biology

Del Ray Beach, Florida · 30,100 · Leased · Semiconductor Mask Repair · X · X · X · X

Emeryville, California · 37,000 · Leased · X · X · X · X

Madison, Wisconsin · 48,000 · Owned · Fluorescence Microscopy · X · X · X · X

Santa Barbara, California · 100,000 · Owned · AFM · X · X · X · X

Seattle, Washington · 41,068 · Leased · X · X · X

BEST · Bergisch Gladbach, Germany · 71,817124,366 · OwnedLeased · Energy & Superconducting · X · X · X · X

Hanau, Germany · 258,872 · Owned · Energy & Superconducting · X · X · X · X

Carteret, New Jersey · 107,300 · Leased · Energy & Superconducting · X · X · X · X

Perth, Scotland · 153,770 · Owned · Energy & Superconducting · X · X · X · X

Shared Use · Billerica, Massachusetts · 203,500 · Owned · Mass Spectrometry · X · X · X · X

Item 2 of the 10-K filed Feb 27, 2026.19

The story

Founded by Günther Laukien in 1960.1

The company was founded on September 7, 1960, in Karlsruhe, Germany as Bruker-Physik AG by five people, one of them being Günther Laukien, who was a professor at the University of Karlsruhe at the time. The name Bruker originates from co-founder Emil Bruker, as Günther Laukien himself was formally not allowed to commercialize his research whilst being a professor. Bruker produced Nuclear Magnetic Resonance Spectroscopy (NMR) and EMR spectroscopy equipment then.

In the early 1960s, the company had around 60 employees and was growing rapidly. One of the early success products was the HFX 90 NMR spectroscopy system, with three independent channels and which was also the first NMR system using only semiconductor transistors.

In 1969, Bruker launched the first commercial Fourier transform NMR spectroscopy system (FT-NMR) and in the 1970s the company was the first to commercialize a superconducting FT-NMR. Later, the company would expand their product range with MRI, FTIR and FT-Raman spectrometers and with mass spectrometers.

In 1968, Bruker shipped NMR systems to Yale University in Connecticut. After that, demand from the US grew, so Bruker opened an office in Elmsford, New York which marked the start of their US activities. In 2008 after a corporate reorganization lasting 8 years, all divisions were merged in a unified Bruker Corporation.

Günther Laukien died in 1997; one of his four sons Frank Laukien, is currently the CEO of Bruker. Another son, Jörg C. Laukien, also works for the company. Another son, Dirk D. Laukien, is a former company executive.

From Wikipedia’s article on Bruker, shared under CC BY-SA 4.0.8

Leadership

Who has led Bruker, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (35)

Products and brands

Bruker develops and delivers a wide variety of professional and scientific analysis devices including mass spectrometers, single-Crystal and powder X-ray diffractometers, X-ray tomography devices, NMR spectroscopy devices, fluorescence microscopes, raman spectroscopes, atomic-force microscopes, and profilometers.

Notable product use

Bruker products are used globally in a variety of situations. The National High Magnetic Field Laboratory at Florida State University selected Bruker to build the world's first 21.0 tesla FT-ICR MS.

The Total Carbon Column Observing Network uses high resolution FT-IR spectrometers made by Bruker to measure various greenhouse gases across the globe.

From Wikipedia’s article on Bruker, shared under CC BY-SA 4.0.8

Subsidiaries and ownership

Subsidiaries

  • Bruker (Canada)
  • Bruker (France)
  • Bruker (Israel)
  • Bruker (Switzerland)
  • Bruker (United States)

Subsidiaries (Exhibit 21)

  • Anasys Instruments Corporation California, U.S.A.9
  • BLI Europe International, LTD United Kingdom9
  • BLI International LLC Delaware, U.S.A.9
  • Biocrates Inc. Delaware, U.S.A.9
  • Biocrates Life Sciences AG Austria9
  • Biognosys, AG Switzerland9
  • Biognosys, Inc. Delaware, U.S.A.9
  • Bruker (Beijing) Scientific Technology Co., Ltd. China9
  • Bruker (Malaysia) SDN. BHD. Malaysia9
  • Bruker AXS Holdings, Inc. Delaware, U.S.A.9
  • Bruker AXS LLC Delaware, U.S.A.9
  • Bruker AXS SE Germany9
  • Bruker Arabia Limited Saudi Arabia9
  • Bruker Austria GmbH Austria9
  • Bruker Belgium S.A./N.V. Belgium9
  • Bruker BioSpin Corporation Massachusetts, U.S.A.9
  • Bruker BioSpin GmbH & Co. KG Germany9
  • Bruker BioSpin Holding SE Germany9
  • Bruker BioSpin Verwaltungs GmbH Germany9
  • Bruker Business Support Center sp. Z.o.o. Poland9
  • Bruker Cellular Analysis, Inc. Delaware, U.S.A.9
  • Bruker DO Brasil Ltda. Brazil9
  • Bruker Daltonics GmbH & Co., KG Germany9
  • Bruker Daltonics Ltd. United Kingdom9
All 127 listed subsidiaries
  • Bruker Daltonik SE Germany9
  • Bruker Detection Corporation Massachusetts, U.S.A.9
  • Bruker EAS Austria AG Austria9
  • Bruker EAS GmbH Germany9
  • Bruker Energy & Supercon Technologies, Inc. Delaware, U.S.A.9
  • Bruker Espanola S.A. Spain9
  • Bruker Finance BV Netherlands9
  • Bruker France S.A.S. France9
  • Bruker India Scientific PVT, Ltd. India9
  • Bruker Invest AG Switzerland9
  • Bruker Italia S.r.l. Italy9
  • Bruker JV UK Ltd. United Kingdom9
  • Bruker Japan K.K. Japan9
  • Bruker Ltd. Canada9
  • Bruker Mexicana S.A. de C.V. Mexico9
  • Bruker Microbiology Technology (Beijing) Co., Ltd China9
  • Bruker Nano GmbH Germany9
  • Bruker Nano, Inc. Arizona, U.S.A.9
  • Bruker Nederland B.V. (a) Netherlands9
  • Bruker Nordic AB Sweden9
  • Bruker Norway AS Norway9
  • Bruker OST LLC Delaware, U.S.A.9
  • Bruker Optics GmbH & Co. KG Germany9
  • Bruker Optics Verwaltungs GmbH Germany9
  • Bruker Optik Holding SE Germany9
  • Bruker PTY Ltd. Australia9
  • Bruker Polska Sp. Z.o.o. Poland9
  • Bruker Portugal Unipessoal LDA Portugal9
  • Bruker Scientific Instrument (Shanghai) Co., Ltd China9
  • Bruker Scientific Instruments Hong Kong Co., Ltd. Hong Kong9
  • Bruker Scientific Israel Ltd. Israel9
  • Bruker Scientific LLC Delaware, U.S.A.9
  • Bruker Singapore Pte. Ltd. Singapore9
  • Bruker South Africa (Pty) Ltd. South Africa9
  • Bruker Spatial Biology, Inc. Delaware, U.S.A.9
  • Bruker Spatial Genomics, Inc. Delaware, U.S.A.9
  • Bruker Switzerland AG Switzerland9
  • Bruker Taiwan Co. Ltd. Taiwan9
  • Bruker Technologies Ltd. Israel9
  • Bruker UK Ltd. United Kingdom9
  • Bruker Verwaltungs GmbH Germany9
  • Bruker s.r.o. Czech Republic9
  • Bruker-Physik GmbH Germany9
  • Canopy Biosciences LLC Delaware, U.S.A.9
  • Chemspeed Technologies AG Switzerland9
  • Chemspeed Technologies GmbH Germany9
  • Chemspeed Technologies Inc. New Jersey, U.S.A.9
  • Chemspeed Technologies Ltd United Kingdom9
  • Dynamic Biosensors GmbH Germany9
  • ELITech Distribution SAS France9
  • ELITech France SAS France9
  • ELITech Group Australia Pty. Ltd. Australia9
  • ELITech Group SAS France9
  • ELITech Mepco SAS France9
  • ELITech UK Ltd. United Kingdom9
  • ELITechGroup Inc. Utah, U.S.A9
  • ELITechGroup MDx LLC Washington, U.S.A.9
  • ELITechGroup New Zealand Limited New Zealand9
  • ELITechGroup SpA Italy9
  • EliTech Microbio SAS France9
  • Fasmatech Science and Technology S.A. Greece9
  • Gonotec GmbH Germany9
  • Hain LifeScience E.A. Ltd. Kenya9
  • Hain LifeScience GmbH Germany9
  • Hydrostatic Extrusions Ltd. United Kingdom9
  • InCoaTec GmbH Germany9
  • InVivo Biotech Services GmbH Germany9
  • International Micobio SAS France9
  • IsoPlexis Corporation Delaware, U.S.A.9
  • IsoPlexis Corporation UK Limited United Kingdom9
  • Luxendo GmbH Germany9
  • MIRO Analytical AG Switzerland9
  • Merlin Diagnostika GmbH Germany9
  • Mestrelab Research S.L. Spain9
  • Molzym GmbH & Co. KG Germany9
  • Molzym Verwaltungs-GmbH Germany9
  • NanoString Technologies Europe Limited United Kingdom9
  • NanoString Technologies Spain, S.L. Spain9
  • Neurescence, Inc. Canada9
  • Optimal Industrial Automation Limited United Kingdom9
  • Optimal Industrial Technologies Limited United Kingdom9
  • Osthus Beteiligungs GmbH Germany9
  • Osthus Group GmbH Germany9
  • Phase Focus Limited United Kingdom9
  • Phasefocus Holdings Limited United Kingdom9
  • Pinpoint Testing, LLC Arkansas, U.S.A.9
  • PreOmics GmbH Germany9
  • PreOmics Inc. Delaware, U.S.A.9
  • Precision Diagnostics, Inc. Delaware, U.S.A.9
  • Prolab Instruments GmbH Switzerland9
  • RECIPE Chemicals + Instruments GmbH Germany9
  • Research Instruments GmbH Germany9
  • Ridom GmbH Germany9
  • SCI Maison de la Biologie France9
  • SmartTip BV Netherlands9
  • Spectral Instruments Imaging LLC Arizona, U.S.A.9
  • TechInvest SARL (a) Luxembourg9
  • Vutara LLC Delaware, U.S.A.9
  • WoBau GmbH Germany9
  • XGLab S.r.l. Italy9
  • Zontal Data Information Technology (Dalian) Co., Ltd. China9
  • Zontal GmbH Germany9
  • Zontal Inc. Florida, U.S.A9

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

Bruker acquisitions include GE NMR Instruments (1992), Siemens AXS (1997), Nonius (2001), MacScience (2002), Vacuumschmelze Hanau (2003), Röntec (2005), SOCABIM (2005), PGT (2005), Keymaster (2006), Quantron (2006), JuWe (2008), SIS (2008), ACCEL (2009), Michrom Bioresources (2011), Skyscan (2012), Prairie Technologies (2013), Oncovision (Preclinical PET imaging business, 2016), Oxford Instruments Superconducting Technology (2016), Hysitron Inc. (2017), XGLab (2017), Luxendo (2017), JPK Instruments (2018), Alicona (2018), PMOD Technologies LLC (2019), Canopy Biosciences (2020), Optimal Group (2022), Neurescence Inc (2022), PhenomeX (2023), MIRO Analytical (majority 2023), NanoString Technologies assets (2024), and ELITechGroup (2024).

Other

In 1964, the company bought the NMR division of the Swiss Trüb-Täuber. Bruker made several offers to take over its supplier Oxford Instruments during the 1970s, but after almost a decade of negotiations, an acquisition was eventually rejected by Oxford Instruments. In 1997, the analytical X-ray division of Siemens was acquired by Bruker. In 2010, Bruker bought 3 product lines from Agilent, which Agilent had acquired from Varian. These included mass spectrometry and gas chromatography instruments. They have since divested these products to Scion Instruments with the exception of the triple quadrupole In 2012, Bruker bought parts of Carestream Health, including their in-vivo imaging portfolio and related aspects.

In 2019, Bruker bought Alicona, known for production of metrology equipment based on focus variation, to extend its analytics business in the industrial market. In 2020, Bruker acquired Canopy Biosciences. This acquisition allowed Canopy to leverage Bruker's global infrastructure and expertise in product design and engineering. The financial terms of the deal were not disclosed. In November 2022, it was announced Bruker had acquired the Mountain View-headquartered miniaturized microscope / miniscope company, Inscopix, Inc.

From Wikipedia’s article on Bruker, shared under CC BY-SA 4.0.8

Former names

  • BRUKER BIOSCIENCES CORPJul 24, 2003 to Feb 27, 20087
  • BRUKER DALTONICS INCJun 20, 2000 to Jul 2, 20037

Timeline

  1. Aug 14, 20268-K Other events67
  2. Aug 4, 20268-K Results of operations68
  3. Jul 30, 20268-K Other events69
  4. May 29, 20268-K Shareholder vote70
  5. May 21, 20268-K Shareholder vote71
  6. May 15, 20268-K Other events72
  7. May 6, 20268-K Results of operations73
  8. Apr 28, 20268-K Other events74
  9. Apr 10, 20268-K Executive or director change75
  10. Apr 1, 20268-K Executive or director change76
  11. Feb 20, 20268-K Executive or director change; Other events77
  12. Feb 12, 20268-K Results of operations78
  13. Mar 16, 2012New chief executive Burkhard Prause becomes CEO20
  14. Jan 9, 2006New chief executive Frank H. Laukien becomes CEO21
  15. 1960Founded Founded1

Calendar

Coming up

  1. Nov 2, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.45 a share, on Nov 3, 2025.79

When it reported results

  1. Aug 4, 2026Reported quarterly or annual results68
  2. May 6, 2026Reported quarterly or annual results73
  3. Feb 12, 2026Reported quarterly or annual results78
  4. Jan 12, 2026Reported quarterly or annual results80
  5. Nov 3, 2025Reported quarterly or annual results81
  6. Aug 4, 2025Reported quarterly or annual results82
  7. Jul 21, 2025Reported quarterly or annual results83
  8. May 7, 2025Reported quarterly or annual results84

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

341 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 59 major events, 159 insider forms, 35 large holders, 68 other. The latest 20:

  1. Sep 16, 20264 EDGAR
  2. Sep 15, 2026144 EDGAR
  3. Aug 18, 20264 EDGAR
  4. Aug 18, 20264 EDGAR
  5. Aug 18, 20264 EDGAR
  6. Aug 18, 20264 EDGAR
  7. Aug 18, 20264 EDGAR
  8. Aug 18, 20264 EDGAR
  9. Aug 18, 20264 EDGAR
  10. Aug 17, 2026144 EDGAR
  11. Aug 14, 2026144 EDGAR
  12. Aug 14, 20268-K EDGAR
  13. Aug 13, 20264 EDGAR
  14. Aug 13, 20264 EDGAR
  15. Aug 13, 20264 EDGAR
  16. Aug 11, 20264 EDGAR
  17. Aug 11, 20264 EDGAR
  18. Aug 11, 20264 EDGAR
  19. Aug 6, 2026SCHEDULE 13G/A EDGAR
  20. Aug 5, 202610-Q EDGAR

The 341 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

45 open-market trades by officers, directors and large owners since October 2021: 6 buys and 39 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 15, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.Sale2,000$52.87$105.7KForm 4
Aug 17, 2026Pusch WolfgangPresident BMID GroupSale3,473$56.90$197.6KForm 4
Aug 14, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.Sale2,000$57.60$115.2KForm 4
Jul 15, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.Sale2,000$60.25$120.5KForm 4
Jun 15, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.Sale2,000$54.76$109.5KForm 4
May 15, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.Sale2,000$43.90$87.8KForm 4
Apr 15, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.Sale2,000$39.90$79.8KForm 4
Mar 13, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.Sale2,000$35.44$70.9KForm 4
Feb 13, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.Sale2,000$36.94$73.9KForm 4
Jan 15, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.Sale2,000$49.20$98.4KForm 4
Jan 12, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.Sale7,000$55.00$385.0KForm 4
Jan 5, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.Sale33,843$49.66$1.7MForm 4
Dec 1, 2025PACKER RICHARD ADirectorSale5,028$48.38$243.3KForm 4
Nov 6, 2025ORNELL JOHN ADirectorSale6,233$39.00$243.1KForm 4
Sep 12, 2025Friend Cynthia MDirectorSale3,535$32.25$114.0KForm 4
Jun 6, 2025LAUKIEN FRANK HPRESIDENT & CEOBuy2,608$38.36$100.0KForm 4
Mar 10, 2025Bures ThomasChief Accounting OfficerBuy500$47.40$23.7KForm 4
Feb 18, 2025LAUKIEN FRANK HPRESIDENT & CEOBuy20,000$50.92$1.0MForm 4
Dec 2, 2024PACKER RICHARD ADirectorSale3,350$57.82$193.7KForm 4
Nov 18, 2024LAUKIEN FRANK HPRESIDENT & CEOBuy100,000$50.14$5.0MForm 4

All 45 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Frank H. LaukienPh.D.$976.6K$4.7M94
2025Mark R. MunchPh.D.$738.4K$2.2M94
2025Gerald N. Herman68$644.2K$2.0M94
2025Juergen W. SregaPresident,71$503.8K$1.4M94
2025Falko BussePh.D. President,$544.6K$1.4M94
2024ChairmanPresident and Chief$965.7K$5.5M94
2024Executive VicePresident and Chief$635.4K$2.3M94
2024Bruker CALIDGroup$477.5K$1.5M94
2024Bruker BioSpinGroup$502.8K$1194
2023Executive Officer$926.1K$5.9M94
2023Bruker NANOGroup$689.9K$2.7M94
2023Financial Officer$603.5K$2.2M94
2023Bruker CALIDGroup$452.5K$1.5M94
2023Bruker BioSpinGroup$468.9K$1194

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC20,237,425$1.2B0.1%+4,135,622
Orbis Allan Gray Ltd17,940,076$1.1B3.7%No change
BlackRock, Inc.11,407,332$686.5M0.0%+226,526
Pallas Capital Advisors LLC9,483,978$570.7M17.6%+2,157
Vanguard Portfolio Management LLC4,888,290$294.2M0.0%+32,375
Vanguard Capital Management LLC4,859,252$292.4M0.0%+42,176
Sculptor Capital LP4,625,000$278.3M4.0%+1,355,000
State Street Corp4,017,673$241.9M0.0%+108,980
Franklin Resources Inc3,229,337$194.3M0.0%+310,160
Sachem Head Capital Management LP2,915,000$175.4M3.6%New
Edmond De Rothschild Holding S.a.2,823,178$169.9M2.2%−533,672
Dimensional Fund Advisors LP2,610,051$157.1M0.0%+268,533
Aqr Capital Management LLC2,512,706$149.5M0.1%+1,219,807
London Co Of Virginia2,480,357$149.3M0.9%−103,672
Geode Capital Management, LLC2,275,361$137.0M0.0%+51,955
First Trust Advisors LP2,065,984$124.3M0.1%+572,931
Morgan Stanley1,834,684$110.4M0.0%−9,984
Artisan Partners Limited Partnership1,491,726$89.8M0.1%+63,945
Brown Advisory Inc1,444,116$86.9M0.1%−336,412
Snyder Capital Management L P1,428,327$86.0M1.5%−39,250
Alyeska Investment Group, L.P.1,410,164$84.9M0.2%+653,007
Charles Schwab Investment Management Inc1,399,125$84.2M0.0%−34,980
Goldman Sachs Group Inc1,142,909$68.8M0.0%+583,080
M&g PLC1,125,556$67.5M0.3%−530,116
Northern Trust Corp988,097$59.5M0.0%+14,975

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

4 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Apr 17, 2023Thomas R Carper, SenateSale$1,001 - $15,000+120.1%Report
Nov 27, 2020Bob Gibbs, HouseSale$1,001 - $15,000+104.1%Report
Nov 20, 2020Thomas R Carper, SenateBuy$1,001 - $15,000−109.8%Report
Jun 24, 2019Donna Shalala, HouseSale$1,001 - $15,000+150.1%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Bruker is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBRUKER CORP2
  • CIK0001109354
  • Employer ID (EIN)04-311016019
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company19
  • Incorporated inDelaware19
  • Fiscal year endsDecember 312
  • Industry code (SIC)3826 Laboratory Analytical Instruments2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address40 Manning Rd, Billerica, MA 018212
  • Phone978663-36602
  • Shares outstanding152,219,250 Common Stock shares; 2,760,000 Series A Mandatory Convertible Preferred Stock shares as of Feb 20, 202619
  • Public float$4.3B as of Jun 30, 202519
  • AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts PCAOB ID 238; it also attests to the company’s internal control over financial reporting19
  • On EDGAR sinceApr 14, 20002
  • Filings1,391 in all: 4 (632), 8-K (263), SC 13G/A (102), 10-Q (79), 3 (44), 144 (32), 10-K (26), DEF 14A (24)2
    All 52 form types

    SC 13G (21), ARS (17), 4/A (13), DEFA14A (13), SD (13), SCHEDULE 13G/A (12), UPLOAD (11), S-8 (8), 8-K/A (7), CORRESP (6), S-1/A (6), 425 (5), 10-Q/A (3), 424B4 (3), 424B5 (3), 5 (3), NT 10-K (3), S-3 (3), S-3/A (3), S-3ASR (3), SC 13D/A (3), 10-K/A (2), 424B3 (2), DEFM14A (2), EFFECT (2), FWP (2), PREM14A (2), SC TO-T/A (2), 3/A (1), 8-A12B (1), 8-A12G (1), CERT (1), CT ORDER (1), D (1), DEFR14A (1), PRER14A (1), S-1 (1), S-4 (1), S-4/A (1), S-8 POS (1), SC 13D (1), SC TO-C (1), SC TO-T (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Feb 27, 2026
    Quarterly report (10-Q) Aug 5, 2026
    Proxy statement (DEF 14A) Apr 10, 2026
    Latest 8-K (8-K) Aug 14, 2026

Securities registered for trading

ClassSymbolExchange
BRKRNasdaq Global Select Market
BRKRPNasdaq Global Select Market

From the cover page of the 10-K filed Feb 27, 2026 (Section 12(b) of the Exchange Act).19

Risk factors and legal proceedings

The risks Bruker names in Item 1A of its 10-K filed Feb 27, 2026: 42 risks under these headings, as written.19

  • Risks Related to Our Business and Industry
  • Supply chain issues, including increasing demand for certain components used in our products and production delays, have and could continue to result in significant additional costs and manufacturing inefficiencies, which could adversely impact our revenue, increase our manufacturing costs and have a material adverse effect on our operating results.
  • Adverse global economic conditions, and geopolitical tensions, including in Ukraine, the Middle East, China and other regions, and other conditions that impact our increasingly global operations could have a negative effect on our business, results of operations and financial condition and liquidity.
  • New U.S. and reciprocal tariffs that have been imposed, and remain subject to potential change and other uncertainties, have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so in the foreseeable future.
  • A meaningful portion of our revenue is derived from U.S. academic institutions, research organizations and other entities that rely in part on U.S. academic and government funding, including NIH, NSF and DOE grants. The current reduction in the level of funding and delay in such research funding, has had a material adverse effect on our U.S. academic and governmental customers, and our business, results of operations and financial condition, and may continue to do so in the foreseeable future.
  • Delays in the release of Chinese government stimulus spending have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so for the foreseeable future.
  • We derive a significant portion of our revenue from international sales and are subject to the operational risks of doing business in foreign countries due to potential macroeconomic effects, including financial market volatility and disruption, inflationary concerns, changes in tax laws and regulations, volatility in interest and currency exchange rates, uncertain economic conditions in the United States and abroad, the impact of the recent U.S. government shutdown, and additional tariffs, including those imposed or that may be imposed by the current administration in the U.S.
  • Our competitive position and reported financial results may be adversely affected when we exchange foreign currency received from international sales into U.S. Dollars and by fluctuations in currency exchange rates.
  • Goodwill, intangible assets and other long-lived assets are subject to impairment which has had and could continue to negatively impact our operating results.
  • If our products fail to achieve and sustain sufficient market acceptance across their broad intended range of applications, we will not generate expected revenue.
  • Our products compete in markets that are subject to rapid technological change, and one or more of the technologies underlying our products could be made obsolete by new technology.
  • We face substantial competition in our industries and expect that such competition will continue. If we fail to compete effectively, it could harm our business results and materially impact the value of our company.
The other 31 risks
  • If investment in life and material science research spending declines, our ability to generate revenue may suffer.
  • Any reduction or shift in the capital resources or government funding of our customers, including as a result of changes to governmental policies and programs, could reduce our sales and impede our ability to generate revenue.
  • Disruptions at any of our manufacturing facilities could adversely affect our business.
  • If employees were to engage in a strike or other work stoppage or interruption, our business, results of operations, financial condition and liquidity could be materially adversely affected.
  • In addition to the risks applicable to our life science and materials analysis products, our CBRNE detection products are subject to a number of additional risks, including lengthy product development and contract negotiation periods and certain risks inherent in long-term government contracts.
  • We rely on information technology to support our operations and reporting environments. A security failure of that technology, including with respect to cybersecurity risks and cyber incidents, could impact our ability to operate our businesses effectively, adversely affect our financial results, damage our reputation and expose us to potential liability or litigation.
  • Our debt, which is principally denominated in foreign currency, is impacted by movement in foreign currency rates which may adversely affect our operations and cash flows and may restrict our investment opportunities or limit our activities.
  • Changes in our effective income tax rate could adversely affect our results of operations.
  • Various international tax risks could adversely affect our earnings and cash flows.
  • The unpredictability and fluctuation of our quarterly results may adversely affect the trading price of our common stock.
  • Our ability to manage and grow our business successfully can be impeded by systems and other technological limitations.
  • Climate change and natural disasters, or legal, regulatory or market measures to address climate change, could adversely affect our business, financial condition or results of operations.
  • The ownership of our shares is highly concentrated, which could cause or exacerbate volatility in our share price as well as have significant influence over us.
  • The loss of key personnel or an inability to attract and retain additional personnel could affect our ability to successfully grow our business.
  • Risks Related to Ownership of our Common Stock
  • The Series A Mandatory Convertible Preferred Stock may adversely affect the market price of our common stock.
  • Our common stock ranks junior to our Series A Mandatory Convertible Preferred Stock with respect to dividends and amounts payable in the event of our liquidation, winding-up or dissolution.
  • Dividends on our common stock could be reduced or eliminated in the future.
  • Risks Related to Our Dependence on Third Parties
  • We face risks related to sales through distributors and other third parties that we do not control, which could harm our business.
  • Dependence on contract manufacturing may adversely affect our ability to bring products to market and damage our reputation.
  • Our operations are dependent upon a limited number of suppliers and contract manufacturers.
  • Supply shortages and increasing prices of raw materials could adversely affect our gross profit.
  • Risks Related to Our Intellectual Property Rights
  • Our success depends on our ability to operate without infringing or misappropriating the proprietary rights of others.
  • If we are unable to effectively protect our intellectual property, third parties may use our technology, which would impair our ability to compete in our markets.
  • We may be involved in lawsuits to protect or enforce our patents that are brought by us which could be expensive and time consuming and, if determined adversely, could adversely affect our patent position.
  • Risks Related to Legal, Regulatory and Compliance
  • Our manufacture and sale of products could lead to product liability claims for which we could have substantial liability.
  • We are subject to environmental laws and regulations, which may impose significant compliance or other costs on us.
  • We are subject to existing and potential additional regulation and government inquiry, which can impose burdens on our operations and narrow the markets for our products.
  • Failure to maintain effective internal controls may cause a loss of investor confidence in the reliability of our financial statements or cause us to delay filing our periodic reports with the SEC and adversely affect our stock price.
  • We operate as an entrepreneurial, decentralized company, which presents certain risks. In particular, significant growth in a decentralized operating model may put strain on certain business group resources and our corporate functions, which could materially and adversely affect our business, financial condition and results of operations.
  • General Risk Factors
  • If we are not able to successfully integrate the businesses we acquire through mergers, acquisitions or strategic alliances, we may not be able to realize all of the cost savings and other benefits that we expect to result from the transactions, and our financial results may be different than expected.
  • Other companies may have difficulty acquiring us, even if doing so would benefit our shareholders, due to provisions under our corporate charter and bylaws, as well as Delaware law.

Legal proceedings

For a discussion of legal matters as of December 31, 2025, please refer to Note 25, Commitments and Contingencies, to our consolidated financial statements included in this report, which is incorporated into this item by reference.

The opening of Item 3, Legal Proceedings.19

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
    SEC EDGAROther events
  68. 68
  69. 69
    SEC EDGAROther events
  70. 70
  71. 71
  72. 72
    SEC EDGAROther events
  73. 73
  74. 74
    SEC EDGAROther events
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94